EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer

Jing Zhang, Wenwei Yang, Junbao Liu, Nan Wang, Zhaoying Ren, Tingting Yang, Gongli Xie, Guifu Wu, Yongkun Sun

Investigational New Drugs · 2024

DOI: 10.1007/s10637-024-01443-1 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Investigational New Drugs, 2024. Verfasst von Jing Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Colorectal Neoplasms, Irinotecan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Beijing Hope Run Special Fund of Cancer Foundation of China, Spark Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This phase I trial is to determine the recommended dose of the TAS-102, irinotecan plus bevacizumab regimen and assess its safety and efficacy in patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin treatment. METHODS: A 3 + 3 designed dose escalation was performed. Patients were administered TAS-102 (30-35 mg/m2 twice daily on days 1-5) and irinotecan (150-165 mg/m2 on day 1) combined with a fixed dose of bevacizumab (5 mg/kg on day 1) every two weeks. The primary endpoint was the determination of the recommended phase II dose. RESULTS: Eighteen patients were enrolled: 6 at the Level 1 (TAS-102 30 mg/m2 twice daily, irinotecan 150 mg/m2 plus bevacizumab 5 mg/kg), six at the Level 2 (TAS-102 35 mg/m2 twice daily, irinotecan 150 mg/m2 plus bevacizumab 5 mg/kg), and six at the Level 3 (TAS-102 30 mg/m2 twice daily, irinotecan 165 mg/m2 plus bevacizumab 5 mg/kg). Five dose-limiting toxicities occurred: one observed at Level 1 (thrombocytopenia), two at Level 2 (neutropenia and diarrhea), and two at Level 3 (fatigue and neutropenia). The RP2D was established as TAS-102 30 mg/m2 twice daily and irinotecan 150 mg/m2 plus bevacizumab 5 mg/kg. The most frequent grade 3/4 treatment-related adverse events were neutropenia (33.3%), diarrhea (16.7%), and thrombocytopenia (11.1%). No treatment-related death occurred. Two patients (11.1%) experienced partial responses and 14 (77.8%) had stable disease. CONCLUSION: The regimen of TAS-102, irinotecan, and bevacizumab is tolerable with antitumor activity for metastatic colorectal cancer patients refractory to first-line fluoropyrimidines and oxaliplatin treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsIrinotecanPyrrolidinesThymineTrifluridineAdultAgedFemaleHumansMaleMiddle AgedDrug CombinationsNeoplasm MetastasisUracil

Stichwörter der Autor:innen

BevacizumabIrinotecanMetastatic colorectal cancer (mCRC)Second-line therapyTrifluridine/tipiracil (TAS-102)

Substanzen

BevacizumabDrug CombinationsIrinotecanPyrrolidinesThymineTrifluridinetrifluridine tipiracil drug combinationUracil

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District Panjiayuan Nan…
  • Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Chaoyang District Shilihe No.352, Beijing, 100122, China.
  • Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Chaoyang District Shilihe No.352, Beijing, 100122, China. 414237191@qq.com.

Förderung

  • Beijing Hope Run Special Fund of Cancer Foundation of China
  • Spark Plan

Zitieren

APA

Zhang, J., Yang, W., Liu, J., Wang, N., Ren, Z., Yang, T., Xie, G., Wu, G., & Sun, Y. (2024). Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01443-1

Vancouver

Zhang J, Yang W, Liu J, Wang N, Ren Z, Yang T, et al. Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer. Investigational New Drugs. 2024. doi:10.1007/s10637-024-01443-1

BibTeX
@article{Zhang2024,
  author = {Zhang, Jing and Yang, Wenwei and Liu, Junbao and Wang, Nan and Ren, Zhaoying and Yang, Tingting and Xie, Gongli and Wu, Guifu and Sun, Yongkun},
  title = {Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer},
  journal = {Investigational New Drugs},
  year = {2024},
  doi = {10.1007/s10637-024-01443-1}
}
Kostenlos starten →